<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777373</url>
  </required_header>
  <id_info>
    <org_study_id>P110902</org_study_id>
    <secondary_id>N° IDRCB : 2012-A00295-38</secondary_id>
    <nct_id>NCT01777373</nct_id>
  </id_info>
  <brief_title>Conducting Airways in Lung Fibrosis (VACFI)</brief_title>
  <acronym>VACFI</acronym>
  <official_title>Conducting Airways in Lung Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether extension of the conducting airways into&#xD;
      the distal lung, or bronchiolization, occurs early in the course of Idiopathic Pulmonary&#xD;
      Fibrosis, a disease wherein normal lung structures are destroyed and replaced by&#xD;
      non-functional scar tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse Interstitial Pneumonias are a heterogeneous group of chronic respiratory diseases.&#xD;
      Idiopathic Pulmonary Fibrosis, one of such diseases, is characterized by lesions of the&#xD;
      conducting airways including extension of bronchioles towards the distal lung, or&#xD;
      bronchiolization of the distal lung. Such lesions are traditionally referred to as &quot;traction&#xD;
      bronchiectasis&quot; although no evidence supports a cause-and-effect relationship between&#xD;
      alveolar fibrosis and airway lesions. Another feature of IPF is chronic, invalidating dry&#xD;
      cough. Our hypothesis is that IPF is characterized by early increases in the volume of&#xD;
      conducting airways, that such changes correlate with cough, and that airway changes are in&#xD;
      direct relation with airway fibrosis. The primary aim of this study is to demonstrate&#xD;
      increased anatomical dead space (VD), a surrogate for conducting airway volume, in patients&#xD;
      with moderate (or early) IPF, in comparison with subjects without any respiratory disease&#xD;
      (&quot;non-DIP controls&quot;). The secondary aims are : To show that VD is increased in patients with&#xD;
      IPF in comparison with patients with other DIPs (&quot;DIP controls&quot;), to show that in patients&#xD;
      with IPF increased VD does not correlate with indices of alveolar fibrosis, and to show&#xD;
      associations between increased VD and cough and other respiratory symptoms in patients with&#xD;
      IPF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fowler dead space</measure>
    <time_frame>1 day</time_frame>
    <description>Conducting airway volume is determined by Fowler's method from volumetric capnography data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bohr anatomic dead space</measure>
    <time_frame>1 day</time_frame>
    <description>Bohr anatomic dead space is determined from capnography and spirometry data.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">141</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Idiopathic pulmonary fibrosis (IPF)</arm_group_label>
    <description>Idiopathic pulmonary fibrosis (IPF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-IPF interstitial lung disease (ILD)</arm_group_label>
    <description>Non-IPF interstitial lung disease (ILD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncharacterized ILD</arm_group_label>
    <description>Uncharacterized ILD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        IPF will be diagnosed according to ATS/ERS/JRS/ALAT 2012 guidelines, either in the presence&#xD;
        of a typical Usual Interstitial Pneumonia pattern on CT imaging of the lung or in the&#xD;
        presence of a probable UIP pattern on a pathological lung specimen, and in the absence of&#xD;
        any identified cause of secondary interstitial pneumonia.&#xD;
&#xD;
        Patients with non-IPF interstitial pneumonias will be recruited. Due to the case mix at&#xD;
        Bichat and Pompidou hospitals, patients with idiopathic Non Specific Interstitial Pneumonia&#xD;
        and interstitial pneumonia associated with sarcoidosis and auto-immune disease will be&#xD;
        recruited.&#xD;
&#xD;
        In some patients, a definitive diagnosis of either IPF or non-IPF interstitial pneumonia&#xD;
        will not be available at the time of inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        IPF :&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Age 18-85 years&#xD;
&#xD;
          2. IPF diagnosed according to ATS/ERS/JRS/ALAT criteria&#xD;
&#xD;
          3. Patient gave informed consent&#xD;
&#xD;
        NON INCLUSION CRITERIA&#xD;
&#xD;
          1. Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema,&#xD;
             tuberculosis sequelae, prior lung surgery&#xD;
&#xD;
          2. Obstructive ventilatory disorder&#xD;
&#xD;
          3. Counterindication to pulmonary function testing&#xD;
&#xD;
          4. Women : Pregnancy or milking&#xD;
&#xD;
          5. Lack of health insurance&#xD;
&#xD;
        Controls :&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Volunteers aged 18-85 years, free of any respiratory disease&#xD;
&#xD;
          2. Volunteer gave informed consent&#xD;
&#xD;
        Secondary EXCLUSION CRITERIA Abnormal PFT : Total lung capacity or FEV1/VC ratio &lt; Lower&#xD;
        Limit of Normal&#xD;
&#xD;
        Non-IPF ILD :&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Age 18-85 years&#xD;
&#xD;
          2. Radiological interstitial pneumonia, on 2 tests performed &gt;3 months apart&#xD;
&#xD;
          3. PINS histology OR sarcoidosis histology OR clinical diagnosis of drug-induced lung&#xD;
             disease OR diagnosis of auto-immune disease&#xD;
&#xD;
          4. Patient gave informed consent&#xD;
&#xD;
        NON INCLUSION CRITERIA&#xD;
&#xD;
          1. Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema,&#xD;
             tuberculosis sequelae, prior lung surgery&#xD;
&#xD;
          2. Obstructive ventilatory disorder&#xD;
&#xD;
          3. Counterindication to pulmonary function testing&#xD;
&#xD;
          4. Women : Pregnancy or milking&#xD;
&#xD;
          5. Lack of health insurance&#xD;
&#xD;
        Uncharacterized ILD :&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Age 18-85 years&#xD;
&#xD;
          2. Radiological interstitial pneumonia, on 2 tests performed &gt;3 months apart&#xD;
&#xD;
          3. Patient gave informed consent&#xD;
&#xD;
        NON INCLUSION CRITERIA&#xD;
&#xD;
          1. Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema,&#xD;
             tuberculosis sequelae, prior lung surgery&#xD;
&#xD;
          2. Obstructive ventilatory disorder&#xD;
&#xD;
          3. Counterindication to pulmonary function testing&#xD;
&#xD;
          4. Women : Pregnancy or milking&#xD;
&#xD;
          5. Lack of health insurance&#xD;
&#xD;
        Secondary EXCLUSION CRITERIA Final diagnosis other than either IPF or non-IPF interstitial&#xD;
        pneumonia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent PLANTIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>conducting airway, bronchiolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

